Cairn Surgical Gains $4.5M in Financing for Novel Breast Cancer Locator System

Cairn Surgical, an innovative medical technology firm striving to make breast cancer surgery more precise, has closed $4.5 million in a Series A2 financing, led by Morningside Ventures.
 
The company will use the funds to complete the currently enrolling U.S. pivotal trial of its Breast Cancer Locator (BCL) System and implement a limited commercial launch in select European markets. 
 
“We are delighted to have the continued support of Morningside Ventures, who believes in our vision of improving both outcomes for breast cancer patients and the healthcare economics of breast cancer surgery,” said Cairn Surgical CEO David Danielsen. “By giving breast cancer surgeons detailed and critical information that they don’t have today, we intend to transform the surgical experience and through that, improve the patient experience, reducing the need for reexcision surgery.”
 
Current Breast Conserving Surgery (BCS) fails to remove the entire tumor roughly 20% of the time, primarily because current breast tumor localization techniques do not provide the information required to achieve precise removal of the entire tumor. 
 
Cairn’s BCL System is designed to improve the accuracy of breast-conserving surgery (lumpectomy) by providing critical information about the tumor to the surgeon, including size, shape, and precise location. An interactive 3D computer model of the tumor in the breast showing tumor shape, size, and location is also provided to the surgeon. 
 
The BCL System is personalized to each patient and based on a supine MRI of the breast in its surgical position for accuracy. The BCL System is a customized 3D-printed form that fits the unique shape of that patient’s breast and is intended to guide the surgeon to the tumor’s boundaries and margins. 
 
“Cairn Surgical has been – and continues to be – a key medtech investment for us,” said Mick Sawka, investment advisor with Morningside Ventures. “The company’s innovative image-derived guidance solution for breast cancer lumpectomy is showing great promise and progress and has shown outstanding clinical results in its European clinical trial. We are excited about its potential to significantly improve patient care, as well as reduce costs to the healthcare system.”